# Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

> **NCT00817219** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 33 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Calcipotriene plus betamethasone dipropionate ointment

## Key facts

- **NCT ID:** NCT00817219
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817219, "Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00817219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*